Silence Therapeutics has named COO Thomas Christely as its new CEO.
He replaces Philip Haworth, who left the company as part of the UK-based company's previously announced reorganization into a wholly European RNAi drugs shop. Haworth was based in California.
Christely served as CFO, and later CEO, of Atugen, an RNAi company that was later acquired by Silence. Before that, he was senior vice president and CFO of OXO Chemie, a Swiss pharmaceutical firm.